Abstract
Duration of acyclovir prophylaxis, mean±SD, weeks 8.9±2.2 10.5±4.4 0.003 Relapse of underlying malignancy after HCT 10 (30.3) 55 (29.9) 0.962 Epstein-Barr virus reactivation 28 (84.8) 141 (76.6) 0.295 Cytomegalovirus reactivation 20 (60.6) 96 (52.2) 0.371 Acute graft-versus-host disease (≥ Grade II) 12 (36.4) 68 (37.0) 0.948 Chronic graft-versus-host disease 9 (27.3) 63 (34.2) 0.434 Overall death* 5 (17.2) 46 (26.0) 0.312
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
